Stock & Company Details
Glaukos Corporation $GKOS
Price:
N/A
N/A
59M
$9.5B
52 Week High:
N/A
10 Day Average Volume:
N/A
-49.47
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
GKOS technical indicators
Latest Glaukos Corporation (GKOS) indicator readings as of 2026-10-09.
GKOS's 14-day RSI is 50.0, in neutral territory. At $165.69 it is trading 21.6% above its 200-day moving average of $136.29, and below its 50-day average of $172.75. Price sits in the middle of its Bollinger Bands ($152.25 to $172.62). ADX reads 18.7, indicating a range-bound market rather than a trend.
GKOS backtested strategy results
How 4 rule-based strategies performed on Glaukos Corporation (GKOS) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +47.0% | 36% | 11 | -39.4% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +58.5% | 43% | 28 | -57.6% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -22.5% | 40% | 35 | -46.4% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +36.9% | 54% | 24 | -42.2% |
Overview
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Finance Bot
Ask your questions
Start by typing a question below.
